Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,870
archived clinical trials in
Pain

An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated:  3/27/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated:  3/27/2018
Clinical Research Facility
mi
from
Saint Louis, MO
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated:  3/27/2018
Clinical Research Facility
mi
from
North Massapequa, NY
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Clinical Research Facility
mi
from
North Massapequa, NY
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated:  3/27/2018
Clinical Research Facility
mi
from
Shawnee Mission, KA
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Clinical Research Facility
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Birmingham, AL
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Sacramento, CA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
San Diego, CA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Brandon, FL
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
DeLand, FL
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Lakeland, FL
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Lakeland, FL
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Ocala, FL
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Orlando, FL
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Tampa, FL
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Columbus, GA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Columbus, GA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Smyrna, GA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Smyrna, GA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Evansville, IN
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Evansville, IN
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
North Dartmouth, MA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
North Dartmouth, MA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Ann Arbor, MI
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Jackson, MS
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Williamsville, NY
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Williamsville, NY
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Middleburg Heights, OH
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Medford, OR
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Portland, OR
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Allentown, PA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Warwick, RI
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Warwick, RI
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Greer, SC
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Dallas, TX
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Charlottesville, VA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Norfolk, VA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Bellevue, WA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Seattle, WA
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Kenosha, WI
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Kenosha, WI
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Cincinnati, OH
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Mount Pleasant, SC
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Birmingham, AL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Oceanside, CA
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
San Diego, CA
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Brandon, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
DeLand, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Ocala, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Orlando, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Tampa, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Jackson, MS
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials